The molecular pharmacology of L-deprenyl
- 5 June 1992
- journal article
- review article
- Published by Elsevier in European Journal of Pharmacology: Molecular Pharmacology
- Vol. 226 (2), 97-108
- https://doi.org/10.1016/0922-4106(92)90170-z
Abstract
No abstract availableKeywords
This publication has 70 references indexed in Scilit:
- Intranigral Iron Injection Induces Behavioral and Biochemical “Parkinsonism” in RatsJournal of Neurochemistry, 1991
- The Iron Chelator Desferrioxamine (Desferal) Retards 6‐Hydroxydopamine‐Induced Degeneration of Nigrostriatal Dopamine NeuronsJournal of Neurochemistry, 1991
- (?)-Deprenyl can induce soluble superoxide dismutase in rat striataJournal of Neural Transmission, 1991
- (−) deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male ratsLife Sciences, 1991
- Turnover of Brain Monoamine Oxidase Measured In Vivo by Positron Emission Tomography Using l‐[11C]DeprenylJournal of Neurochemistry, 1987
- Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson's disease: A longterm studyJournal of Neural Transmission, 1985
- Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidaseBiochemical and Biophysical Research Communications, 1984
- IMPLICATIONS OF COMBINED TREATMENT WITH 'MADOPAR' AND L-DEPRENIL IN PARKINSON'S DISEASEThe Lancet, 1977
- The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formationEuropean Journal of Pharmacology, 1975
- The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenilJournal of Neural Transmission, 1975